Immune checkpoint inhibitors: possibility of adverse rheumatoid events

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • The incidence of rheumatic immune-related adverse events (IRAEs) resulting from treatment with immune checkpoint inhibitors (ICI) remains unclear, but significant.

Why this matters

  • Physicians should be aware of the potential for rheumatoid side effects of ICI treatment.

Study ...